CN105407901A - 癌症治疗 - Google Patents

癌症治疗 Download PDF

Info

Publication number
CN105407901A
CN105407901A CN201480020906.8A CN201480020906A CN105407901A CN 105407901 A CN105407901 A CN 105407901A CN 201480020906 A CN201480020906 A CN 201480020906A CN 105407901 A CN105407901 A CN 105407901A
Authority
CN
China
Prior art keywords
mycobacteria
cancer
tumor
carcinoma
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480020906.8A
Other languages
English (en)
Chinese (zh)
Inventor
T·哈格曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immodulon Therapeutics Ltd
Original Assignee
Immodulon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immodulon Therapeutics Ltd filed Critical Immodulon Therapeutics Ltd
Publication of CN105407901A publication Critical patent/CN105407901A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
CN201480020906.8A 2013-05-09 2014-05-09 癌症治疗 Pending CN105407901A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1308325.8A GB201308325D0 (en) 2013-05-09 2013-05-09 Cancer Therapy
GB1308325.8 2013-05-09
PCT/GB2014/051421 WO2014181121A1 (en) 2013-05-09 2014-05-09 Cancer therapy

Publications (1)

Publication Number Publication Date
CN105407901A true CN105407901A (zh) 2016-03-16

Family

ID=48672024

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480020906.8A Pending CN105407901A (zh) 2013-05-09 2014-05-09 癌症治疗

Country Status (18)

Country Link
US (1) US20160074494A1 (enExample)
EP (1) EP2994148B8 (enExample)
JP (1) JP2016520057A (enExample)
KR (1) KR20160022803A (enExample)
CN (1) CN105407901A (enExample)
AU (1) AU2014264434A1 (enExample)
BR (1) BR112015025719A2 (enExample)
CA (1) CA2907841A1 (enExample)
DK (1) DK2994148T3 (enExample)
ES (1) ES2618050T3 (enExample)
GB (1) GB201308325D0 (enExample)
HU (1) HUE031783T2 (enExample)
MX (1) MX2015014344A (enExample)
PL (1) PL2994148T3 (enExample)
RU (1) RU2015143106A (enExample)
SG (1) SG11201507847UA (enExample)
SI (1) SI2994148T1 (enExample)
WO (1) WO2014181121A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
PL3319635T3 (pl) * 2015-06-24 2021-10-25 Immodulon Therapeutics Limited Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej
KR101832892B1 (ko) * 2015-08-24 2018-02-27 가톨릭대학교 산학협력단 면역억제제로 유발되는 미토콘드리아 질환 및 면역 질환의 예방 또는 치료를 위한 메트포민을 포함하는 조성물
GB201601248D0 (en) * 2016-01-22 2016-03-09 Immodulon Therapeutics Ltd Cancer therapy
GB201608806D0 (en) * 2016-05-19 2016-07-06 Immodulon Therapeutics Ltd Method
WO2018112364A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating melanoma
WO2018112360A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
WO2019075452A1 (en) * 2017-10-13 2019-04-18 Evelo Biosciences, Inc. IDENTIFICATION OF BACTERIA FOR CANCER THERAPY
CN109329204B (zh) * 2018-10-12 2021-02-12 中国医学科学院北京协和医院 胰腺癌动物模型的构建方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085466A1 (en) * 2008-01-29 2009-08-05 AEterna Zentaris GmbH Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369542C (en) 1999-04-23 2009-10-27 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
WO2006109300A1 (en) 2005-04-14 2006-10-19 Hadasit Medical Research Services & Development Ltd. Pre-transplantation treatment of donor cells to control graft versus host disease (gvhd) in transplant recipients
WO2008110491A2 (en) * 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
ES2567753T3 (es) * 2009-07-08 2016-04-26 Baltic Bio Ab Derivados de 1,2,4-tiazolidin-3-ona y su uso en el tratamiento del cáncer
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
US8617520B2 (en) * 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085466A1 (en) * 2008-01-29 2009-08-05 AEterna Zentaris GmbH Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof
CN101965395A (zh) * 2008-01-29 2011-02-02 阿特纳赞塔里斯有限公司 能够在巨噬细胞中诱导凋亡的非致病性的和/或减毒的细菌、其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
庄宝玲等: "偶然分枝杆菌形态变化的超微结构的研究", 《中国人兽共患病杂志》 *
陈虹等: "母牛分枝杆菌菌苗的临床应用研究进展", 《医药导报》 *

Also Published As

Publication number Publication date
WO2014181121A1 (en) 2014-11-13
SI2994148T1 (sl) 2017-07-31
JP2016520057A (ja) 2016-07-11
HUE031783T2 (en) 2017-07-28
RU2015143106A (ru) 2017-06-15
CA2907841A1 (en) 2014-11-13
AU2014264434A1 (en) 2015-10-08
BR112015025719A2 (pt) 2017-07-18
PL2994148T3 (pl) 2017-07-31
EP2994148B1 (en) 2017-02-01
ES2618050T3 (es) 2017-06-20
EP2994148A1 (en) 2016-03-16
MX2015014344A (es) 2016-06-21
EP2994148B8 (en) 2017-08-30
US20160074494A1 (en) 2016-03-17
DK2994148T3 (en) 2017-03-13
GB201308325D0 (en) 2013-06-19
KR20160022803A (ko) 2016-03-02
SG11201507847UA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
CN105407901A (zh) 癌症治疗
Assi et al. Gene therapy for brain tumors: basic developments and clinical implementation
Le Naour et al. Trial watch: Toll-like receptor ligands in cancer therapy
AU767892B2 (en) New combined preparation for the treatment of neoplasic diseases or of infectious diseases
Xiong et al. Advanced treatment in high-grade gliomas
KR20190128050A (ko) 종양용해성 바이러스 요법
BR112016013887B1 (pt) Uso de um inibidor do ponto de verificação e de uma micobactéria morta pelo calor não patogênica de variante bruta para terapia de câncer
US10039825B2 (en) Combination therapy with CD4 lymphocyte depletion and MTOR inhibitors
US8617520B2 (en) Cancer therapy
US20220054614A1 (en) Inhibition of asph expressing tumor growth and progression
Yao et al. Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-β2 inhibitor
US20250186438A1 (en) Treatment of clear cell renal cell carcinoma
CN109674788B (zh) 羧胺三唑与ido1抑制剂组合在抗肿瘤中的用途
CN101448514A (zh) 黑素瘤的治疗
Gazit et al. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines
Tomita et al. Histamine regulates growth of malignant melanoma implants via H2 receptors in mice
Shurin et al. Cancer therapy and dendritic cell immunomodulation
Abikenari Contemporary Advances and Challenges in the Treatment of Glioblastoma (GBM): The role of Immunotherapy and Small-Molecule Inhibitors as potential therapeutic strategies
US20230405059A1 (en) A mycobacterium for use in cancer therapy
WO2024222787A1 (zh) 一种药物组合物及其制备方法和用途
US20210153848A1 (en) Skin cancer treatment
WO2023245248A1 (en) Treatment of melanoma
Alonso et al. 269 POSTER Targeting brain tumor stem cells with oncolytic virus in combination with temozolomide
Lane et al. 41 Applications of the inhibition of Mdm2 function in Cancer Therapy
JP2004514683A (ja) レバミゾール及び５−フルオロウラシルの同時投与法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160316

WD01 Invention patent application deemed withdrawn after publication